TrialThe oncologist2024

Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).

Ikuko Hirai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.